**United Therapeutics (UTHR) Stock Rises 12.5% Following Positive Study Results**
United Therapeutics Corporation’s shares surged 12.5% to $588.36 in the last trading session, significantly exceeding its 3.8% gain over the past four weeks. This rise came after the company reported encouraging data from its Phase III TETON-1 study involving nebulized Tyvaso for the treatment of idiopathic pulmonary fibrosis (IPF), highlighting its primary endpoint achievement of change in absolute forced vital capacity (FVC) from baseline to week 52.
The company plans to submit a supplemental new drug application to the FDA by the end of summer for priority review of nebulized Tyvaso in treating IPF. Analysts predict United Therapeutics will report quarterly earnings of $6.72 per share, reflecting a year-over-year increase of 1.4%, and revenues are expected to reach $809.15 million, up 1.9% from the same quarter last year.
